Overview
- Authors:
-
-
Ian Fentiman
-
Research Oncology, Guy’s Hospital, London, United Kingdom
- Provides a comprehensive and authoritative overview of the diagnosis and treatment of a rare disease
- Data are summarised in tables, providing enhanced clarity
- Offers an up-to-date resource of available data allowing for evidence-based decision making
Access this book
Other ways to access
Table of contents (12 chapters)
About this book
This book provides an up-to-date review of the risk factors and genetics influencing the development of this rare disease. This volume presents clinical features and recent advances in histopathology and molecular profiling are analyzed, providing a valuable aid to clinicians in tailoring treatment to both the patient and the tumour. Readers will find important insights into the most effective strategies for making or negating a diagnosis of MBC. Within this timely volume, consideration is also given to the psychological needs of men with breast cancer alongside a discussion of the most effective support methods. The surgical management of the disease is examined, together with algorithms for local and systemic therapy. Owing to the problem of late diagnosis in MBC, many men have advanced or disseminated disease at diagnosis and, as such, the evidence-based management of these cases is reviewed. Male Breast Cancer concludes with a discussion on determiningprognosis and the likely future developments in MBC with a focus on improved diagnosis and survival. Male Breast Cancer will be of interest to breast surgeons, oncologists, breast radiologists, breast histopathologists and breast care nurses worldwide.
Authors and Affiliations
-
Research Oncology, Guy’s Hospital, London, United Kingdom
Ian Fentiman
About the author
Consultant Surgeon, Guy's Hospital, London 1982 Professor of Surgical Oncology, Guy's Hospital, London 1996 Awards Arris and Gale Lecturer Royal College of Surgeons of England 1978 Keith Durrant Memorial Lecture British Oncological Association 1991 Honoured by Cancer Care for advancing treatment of early breast cancer as one of the 100 Investigators published most frequently in the 20th century. San Antonio December 2000.
